Transanal endoscopic microsurgery as day surgery - a single-centre experience with 500 patients

被引:4
作者
Brown, C. J. [1 ,2 ,3 ]
Gentles, J. Q. [3 ]
Phang, T. P. [1 ,2 ,3 ]
Karimuddin, A. A. [1 ,2 ,3 ]
Raval, M. J. [1 ,2 ,3 ]
机构
[1] Univ British Columbia, Dept Surg, Vancouver, BC, Canada
[2] St Pauls Hosp, Vancouver, BC, Canada
[3] Univ British Columbia, Dept Surg, Vancouver, BC, Canada
关键词
Transanal endoscopic microsurgery; rectal cancer; length of stay; outpatient procedure; MINIMALLY INVASIVE SURGERY; RECTAL LESIONS; TERM OUTCOMES; SAFE; EXCISION; CANCER; DEFECT;
D O I
10.1111/codi.14337
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AimTransanal endoscopic microsurgery (TEM) is the current treatment of choice for rectal adenomas and early rectal cancer. Postoperative admission to hospital is common but possibly unnecessary. Our objective was to analyse predictors and outcomes of TEM patients having same day discharge (TEM-D) compared with those who were admitted to hospital (TEM-A). MethodAt St Paul's Hospital (SPH), demographic, surgical, pathological and follow-up data have been collected prospectively since TEM was started in 2007. Trends in admission and readmission rates were analysed using the Cochran-Armitage trend test, and predictors of admission were analysed using univariate and multivariate logistic regressions. ResultsBetween 2007 and 2016, 500 patients were treated by TEM at SPH. The overall admission rate was 29% (145/500), but this decreased to 19% in the last 3 years of the study (P < 0.001). The readmission rate was 5.2% (n = 26/500) and did not change significantly over the study period (P = 0.30). Reasons for admission included the following: surgeon discretion/monitoring (35%), urinary retention (26%), haemorrhage (10%), breach of peritoneal cavity (7%), infection (7%) and other (15%). The most common reasons for readmission were haemorrhage (54%, n = 14), pain (19%, n = 5) and infection (12%, n = 3). Factors associated with admission were as follows: tumour height (OR 1.09, 1.02-1.17), prolonged operative time (OR 1.25, 1.14-1.37), unsutured surgical defect (OR 1.99, 1.22-3.25) and surgeon experience (OR 4.62, 2.75-7.77). ConclusionOutpatient TEM is safe and carries a low risk of readmission. In centres with an outpatient TEM strategy, predictors of hospital admission include proximal tumours, prolonged surgical time and open management of the surgical defect.
引用
收藏
页码:O310 / O315
页数:6
相关论文
共 22 条
[1]   Long-term functional results and quality of life after transanal endoscopic microsurgery [J].
Allaix, M. E. ;
Rebecchi, F. ;
Giaccone, C. ;
Mistrangelo, M. ;
Morino, M. .
BRITISH JOURNAL OF SURGERY, 2011, 98 (11) :1635-1643
[2]   Transanal Endoscopic Microsurgery for Rectal Neoplasms: Experience of 300 Consecutive Cases [J].
Allaix, Marco Ettore ;
Arezzo, Alberto ;
Caldart, Mario ;
Festa, Federico ;
Morino, Mario .
DISEASES OF THE COLON & RECTUM, 2009, 52 (11) :1831-1836
[3]   Why the Conventional Parks Transanal Excision for Early Stage Rectal Cancer Should Be Abandoned [J].
Atallah, Sam ;
Keller, Deborah .
DISEASES OF THE COLON & RECTUM, 2015, 58 (12) :1211-1214
[4]   Transanal minimally invasive surgery: a giant leap forward [J].
Atallah, Sam ;
Albert, Matthew ;
Larach, Sergio .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2010, 24 (09) :2200-2205
[5]   Day surgery in Scotland: patient satisfaction and outcomes [J].
Bain, J ;
Kelly, H ;
Snadden, D ;
Staines, H .
QUALITY IN HEALTH CARE, 1999, 8 (02) :86-91
[6]   Day-case closure of ileostomy: feasible, safe and efficient [J].
Bhalla, A. ;
Peacock, O. ;
Tierney, G. M. ;
Tou, S. ;
Hurst, N. G. ;
Speake, W. J. ;
Williams, J. P. ;
Lund, J. N. .
COLORECTAL DISEASE, 2015, 17 (09) :820-823
[7]   The surgical defect after transanal endoscopic microsurgery: open versus closed management [J].
Brown, Carl ;
Raval, Manoj J. ;
Phang, P. Terry ;
Karimuddin, Ahmer A. .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2017, 31 (03) :1078-1082
[8]   Advances in minimally invasive surgery in the treatment of colorectal cancer [J].
Brown, Carl J. ;
Raval, Manoj J. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (01) :111-123
[9]  
BUESS G, 1984, CHIRURG, V55, P677
[10]  
D'Hondt M, 2017, JSLS, V21, P1